Skip to main content
You have permission to edit this article.
Edit
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

108.93 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Dec 6, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
49 50 Next >
Why Is Gossamer Bio (GOSS) Stock Down Over 70% Today?
GOSS stock is plunging over 70%. The company's hypertension drug reportedly failed to perform better than a competing treatment. 
Via InvestorPlace
Mirati Therapeutics Crashes As The Cancer Rivalry With Amgen Heats Up
The combination with Keytruda appears safe, but effectiveness questions persist. 
Via Investor's Business Daily
Mirati Experimental Lung Cancer Drug Shows Favorable Tolerability, Promising Efficacy
 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Apollo Endosurgery, Inc. (Nasdaq - APEN), Imago BioSciences, Inc. (Nasdaq - IMGO), Opiant Pharmaceuticals Inc. (Nasdaq - OPNT), Benefitfocus, Inc. (Nasdaq - BNFT)
From Brodsky & Smith LLC
Via Globe NewsWire
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today
 
Via Benzinga
Merck's Keytruda Phase 3 Trial Meets Primary Endpoint In Gastric Cancer Patients
 
Via Benzinga
Will Black Friday Push The S&P 500 Over Its 200DMA?
U.S. stocks reversed the rally spurred by inflation data. Fed officials dispelled hopes that the central bank would moderate interest rate increases. 
Via Talk Markets
What Bear Market? This Top-Performing Dow Stock Has Thrived in 2022.
The company is having a record-smashing year. 
Via The Motley Fool
Should Investors Consider These 3 Low-Beta Stocks?
A hawkish Federal Reserve has been a thorn in the side of many stocks in 2022, causing widespread volatility. Other than energy, the market landscape has been dim. 
Via Talk Markets
Merck & Co Unusual Options Activity
Someone with a lot of money to spend has taken a bearish stance on Merck & Co (NYSE:MRK). And retail traders should know. We noticed this today when the big position showed up on publicly available... 
Via Benzinga
Merck to Present Data From Its Hematology Portfolio and Promising Pipeline at the 64th American Society of Hematology (ASH) Annual Meeting
From Merck & Co., Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's session, 108 stocks hit new 52-week highs. 
Via Benzinga
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope
EQNX::TICKER_START (OTCQB:BVAXF),(NASDAQ:CTIC),(NASDAQ:SGEN),(NYSE:MRK),(NASDAQ:IMGN) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Intellectual Property
Exposures Intellectual Property
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Merck Announces First-Quarter 2023 Dividend
From Merck & Co., Inc.
Via Business Wire
3 Dow Stocks to Take Seriously in 2023
The top Dow stocks for 2023 are all big free cash flow generators that ought to be able to cope with whatever next year brings. 
Via InvestorPlace
Cramer Expects Dow's Outperformance To Last 'Longer' As Traders Chase 'Old-Fashioned, Profitable' Companies Amid Uncertainty
The Dow Industrials Average, a price-weighted average that tracks the performance of 30 blue-chip stocks, has outperformed the broader S&P 500 Index and the tech-weighted Nasdaq Composite 
Via Benzinga
3 Reasons Pfizer Stock Will Crush the Broader Market in 2023
Pfizer's revenue growth is far from over. 
Via The Motley Fool
Stocks Take A Hit As Wall Street Eyes China Covid Unrest
st week's mostly upbeat sentiment was forgotten on Monday as investors anxiously eyed the pushback the Chinese government is receiving for its prolonged Covid-19 restrictions. 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Merck & Co Unusual Options Activity
A whale with a lot of money to spend has taken a noticeably bullish stance on Merck & Co. Looking at options history for Merck & Co (NYSE:MRK) we detected 16 strange trades. 
Via Benzinga
2 Biotech Stocks You Can Buy and Hold for the Next Decade
These two companies are facing short-term issues that are likely to give way to long-term success. 
Via The Motley Fool
3 Biotech Stocks Smart Investors Should Be Buying Up Now
These three biotech stocks could be among the best ways to play this uncertain market for those looking for long-term growth. 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Friday
  On Friday, 68 companies reached new 52-week highs. 
Via Benzinga
7 Stocks on the Perfect 10 List
Companies that have strong quality, value, or growth grades are the stocks to buy once markets recognize their business potential. 
Via InvestorPlace
Mirati Therapeutics Surges As Big Pharma Reportedly Preps For A Buyout Battle
There are reportedly numerous companies in the mix and they're all awaiting data next month. 
Via Investor's Business Daily
See Why Gilead's Cancer Business Is Driving The Stock To A Fever Pitch
Sales accelerated, again, in the third quarter. Here's what the company and analysts are watching. 
Via Investor's Business Daily
Mirati Therapeutics Garners Interest From Large Pharmas Ahead Of Much Awaited Data Next Month
Mirati Therapeutics Inc (NASDAQ: MRTX) is reportedly amid fresh takeover interest from large pharmaceutical companies ahead of updates on its drug pipeline.  For some time, the cancer-focused company... 
Via Benzinga
10-Year Phase 3 Trial Shows CEL-SCI's Multikine immunotherapy Extends Lives In Head & Neck Cancer Patients
 
Via Benzinga
First Patients Dosed in Phase I/II Trial of Enlivex's Off-the-Shelf Cell Therapy Candidate, AllocetraTM
On November 13, Enlivex (NASDAQ: ENLV) announced that the first patient has been dose 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
49 50 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.